The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.


Report Claims MOST HCV Patients Will Develop Cirrhosis

Back to News Homepage


New Drug, Actilon, In Development

Another Treatment Development Alliance

September 14, 2005

Print this page

Alnylam to align with West Coast firm on hep C treatment

Boston Business Journal

Alnylam Pharmaceuticals Inc. and a California company have signed a joint licensing deal for a gene that could help treat hepatitis C.

The Cambridge, Mass. company (Nasdaq: ALNY) and Isis Pharmaceuticals Inc. of Carlsbad (Nasdaq: ISIS) announced on Tuesday that they inked a combined licensing agreement with Stanford University.

They’ll gain co-exclusive access to Stanford research regarding a MicroRNA gene found to be needed to replicate the hepatitis C virus in mammalian cells.

Researchers hope the discovery could lead to treatments for hepatitis C, a viral infection of the liver that can cause cirrhosis and liver cancer. Researchers estimate 170 million people globally have hepatitis c infections. Vaccines don’t exist yet to prevent the disease.

Alnylam announced on Sept. 7 that it had signed a multi-year alliance with Novartis AG that could be worth more than $700 million if the deal produces commercial products.

Alnylam and Novartis (NYSE: NVS) will work on developing RNAi therapies. RNAi is a natural process within cells that selectively silences genes, and Alnylam believes RNAi can treat disease by silencing genes that cause disease.

In the short term, Novartis will pay Alnylam $56.8 million, through cash and a purchase of 4.2 shares of Alnylam common stock.

Requirements for using and reposting articles